The Meaning of Informed Consent: Genome Editing Clinical Trials for Sickle Cell Disease
{{output}}
A first therapeutic target of somatic genome editing (SGE) is sickle cell disease (SCD), the most commonly inherited blood disorders, affecting more than 100,000 individuals in the United States. Advancement of SGE is contingent on patient participation in fir... ...
